Related Experiment Video

Updated: Jul 23, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.6K

The role of the MDM2/p53 axis in antitumor immune responses

Tilman Brummer1,2,3,4, Robert Zeiser2,3,4,5

  • 1Faculty of Medicine, Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany.

Blood
|July 19, 2023
PubMed

Insights

Inhibiting mouse double minute 2 homolog (MDM2) can restore tumor suppressor p53 function and enhance anti-tumor immunity. This approach shows promise for treating acute myeloid leukemia and solid tumors, especially when combined with other immunotherapies.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Mouse double minute 2 homolog (MDM2) negatively regulates the tumor suppressor p53.
  • High MDM2 expression is common in acute myeloid leukemia (AML) and solid tumors.
  • TP53 mutations in AML indicate a poor prognosis and increased relapse risk.

Purpose of the Study:

  • To review how manipulating MDM2 and p53 can enhance cancer cell immunogenicity.
  • To discuss MDM2/p53 regulation of immune-related factors in cancer.
  • To explore MDM2 inhibition as a strategy for cancer immunotherapy.

Main Methods:

  • Literature review of MDM2 and p53 roles in cancer immunity.
  • Analysis of MDM2/p53 regulation of MHC, dsRNA, interferons, IL-15, and TRAIL-Rs.
  • Examination of MDM2 inhibition effects on T cells and preclinical/clinical data.

Main Results:

  • MDM2 inhibition can restore p53 function and enhance anti-tumor immunity.
  • MDM2/p53 influence key immune pathways, including MHC expression and cytokine production.
  • Direct effects of MDM2 inhibition on T cells contribute to immunotherapy.

Conclusions:

  • MDM2 inhibition is a promising strategy to restore p53 and boost anti-tumor immunity.
  • Targeting MDM2 offers a novel approach for combined immunotherapy in hematological malignancies and beyond.
  • Restoring p53 and directly impacting T cells via MDM2 inhibition represent an emerging immunotherapy concept.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

434
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K